Anthracyline-reduced sequential combination chemotherapy for younger patients with good-prognosis aggressive B-cell non-Hodgkin's lymphoma.

Introduction Anthracyline-based chemotherapy is the treatment of choice for patients with aggressive B-cell non-Hodgkin’s lymphoma (NHL). However, anthracyclines have been associated with long-term cardiac toxicity.